Company insight The cold chain dilemma
Life sciences logistics is under pressure to balance product safety, sustainability and cost. Altor argues that flexibility – with a portfolio of both traditional and next-generation packaging – will define the future of temperature-controlled supply chains.
Additionally, there’s the consideration of the impact any change will have on an organisation, especially when testing and qualification are part of any new solution. This is where variants on existing technologies, like the predominantly recycled content EmeraldPak, can be helpful; providing the tried-and-tested performance of EPS, but with sustainable attributes already built in.
The next hurdle Altor is taking a ‘material-neutral’ approach, offering a spectrum of traditional and innovative technologies. I
n the high-stakes world of life sciences logistics, the integrity of temperature-sensitive shipments is non-negotiable. Biologics, vaccines and speciality pharmaceuticals must arrive on time and in compliance with strict regulations. Yet pressure to reduce environmental impact and manage costs is growing.
This is driving a shift in how packaging decisions are made. Industry players like Altor are taking a more ‘material- neutral’ approach, offering a spectrum of traditional technologies like EPS, and innovative technologies that give trusted performance but with an added sustainable advantage – like BioEPS or the recently launched EmeraldPak – that let life sciences companies meet performance requirements while advancing their sustainability goals.
Make the right decision The decision-making process on materials is rarely straightforward. Traditional materials have a longer track record of success but may not meet the environmental goals of your company. On the other hand, opting for a newer material brings a level of risk that needs to be mitigated through extra
www.worldpharmaceuticals.net
qualification or increased education to end users.
Additionally, these decisions often involve smaller but meaningful trade- offs – higher upfront cost, changes to disposal methods or adjustments to payload configuration. But just because something is difficult doesn’t mean it isn’t worth it in the long run, which leads us to ‘the cold chain dilemma’.
This ‘cold-chain dilemma’ is the balancing act life sciences companies face – meeting performance targets and safeguarding product integrity while advancing environmental goals and ensuring operational teams can execute. Sometimes this dilemma affects a single packaging configuration; other times it requires reassessing the entire packaging portfolio.
Turn to the right partner Senior leaders in this industry are increasingly turning to trusted packaging manufacturers who can provide a diversified, consultative packaging approach to account for different products, shipping lanes, temperature requirements and internal processes. Sometimes, an off-the-shelf solution will fit, but other times, a more customised approach is necessary.
Once you’ve selected a material (or set of materials), validation and qualification often become the next hurdles. Thermal modelling can streamline the design process and reduce the number of physical tests required, but full qualification in an ISTA-certified lab is critical. Certified facilities provide repeatable, standards-based data that supports regulatory compliance and builds confidence across quality, operations and supply chain teams. This step becomes even more important when introducing newer, sustainable materials that may not yet have decades of field data behind them. Proper qualification ensures that sustainability initiatives do not compromise patient safety or product efficacy while at the same time helping organisations to be more dynamic in navigating through a change towards sustainability. For senior leaders, the takeaway is clear: the future of cold chain packaging is about having options and deploying them intelligently. Manufacturers like Altor are building portfolios that combine sustainable, traditional and hybrid solutions, supported by certified lab validation. For life sciences companies navigating complex supply chains, this flexibility can be the difference between staying ahead of regulatory, environmental and market pressures, or falling behind. ●
https://altorsolutions.com 27
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85
